Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 170Rituximab 164Specimen Handling 116Biopsy 92Magnetic Resonance Spectroscopy 90Vincristine 86Doxorubicin 81Prednisone 78fludarabine 70venetoclax 69obinutuzumab 62ibrutinib 55Lenalidomide 55Dexamethasone 55Cytarabine 49Methotrexate 47acalabrutinib 44Etoposide 43CT-P10 42blinatumomab 38fludarabine phosphate 35Bendamustine Hydrochloride 34Gemcitabine 33zanubrutinib 31prednylidene 31pembrolizumab 30glofitamab 30deltacortene 30Calcium Dobesilate 30Nivolumab 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ferric pyrophosphate × Lymphoid × 90 days × Clear all
NCT01318317 2026-05-05

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center

Phase 1/2 Active not recruiting
8 enrolled 13 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡